WORLD HEALTH ORGANIZATION

ONL Therapeutics has randomized the first patient in its global Phase 2 GALAXY trial evaluating xelafaslatide, a first-in-class Fas inhibitor for geographic atrophy associated with dry AMD.

Amprologix is completing preclinical safety studies for Epidermicin NI01, a first-in-class antibiotic designed to treat resistant skin and other bacterial infections.

A coalition of families and patient advocates has launched a buyers' club to distribute a generic version of Vertex Pharmaceuticals' Trikafta, priced at $6,375 annually for children compared to Vertex's $370,000 US list price.

A comprehensive French study of over 527,000 infants found no increased risk of major congenital malformations among babies exposed to mRNA COVID-19 vaccines during the first trimester of pregnancy.

SK bioscience has submitted a Phase 1/2 clinical trial application in Australia for GBP511, a universal coronavirus vaccine designed to protect against COVID-19 variants and broader sarbecoviruses.

Researchers at CRCHUM will launch the RESTART trial this fall to test whether fostemsavir can improve cardiovascular health in HIV patients by targeting the toxic viral protein gp120.

The World Health Organization reports a concerning decrease in antibacterial agents under development, dropping from 97 in 2023 to 90 in 2025, with only 15 qualifying as innovative treatments.

Recce Pharmaceuticals has begun patient dosing in its registrational Phase 3 clinical trial of RECCE® 327 Topical Gel for diabetic foot infections in Indonesia, targeting up to 310 patients across five clinical sites.

Globe Biotech Limited has obtained the first US pharmaceutical patent in Bangladesh's 54-year history for its COVID-19 vaccine Bangavax, marking a significant milestone for the country's pharmaceutical industry.

A large UK retrospective study of 624,308 adults found that metformin initiated within 90 days of COVID-19 infection reduced Long COVID risk by 64% in overweight or obese individuals.